Your browser doesn't support javascript.
loading
Genotype-phenotype findings in patients with mucopolysaccharidosis II from the Hunter Outcome Survey.
Muenzer, Joseph; Amartino, Hernan; Burton, Barbara K; Scarpa, Maurizio; Tylki-Szymanska, Anna; Audi, Jennifer; Botha, Jaco; Fertek, Daniel; Merberg, David; Natarajan, Madhusudan; Whiteman, David A H; Giugliani, Roberto.
Afiliación
  • Muenzer J; University of North Carolina at Chapel Hill, 101 Manning Drive CB# 7487, Medical School Wing E Room 117, Chapel Hill, NC 27599-7487, USA. Electronic address: muenzer@med.unc.edu.
  • Amartino H; Servicio de Neurología Infantil, Hospital Universitario Austral, Pilar, Buenos Aires, Argentina. Electronic address: hernan.amartino@gmail.com.
  • Burton BK; Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, 225 E. Chicago Avenue, Chicago, IL 60611, USA. Electronic address: BBurton@luriechildrens.org.
  • Scarpa M; Regional Coordinating Center for Rare Diseases, Udine University Hospital, P.le S. Maria della Misericordia 15, Udine 33100, Italy. Electronic address: maurizio.scarpa@asufc.sanita.fvg.it.
  • Tylki-Szymanska A; Department of Metabolic Diseases, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland. Electronic address: atylki@op.pl.
  • Audi J; Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Glattpark (Opfikon), Zurich, Switzerland. Electronic address: jennyaudi@gmail.com.
  • Botha J; Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Glattpark (Opfikon), Zurich, Switzerland. Electronic address: jaco.botha@takeda.com.
  • Fertek D; Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Glattpark (Opfikon), Zurich, Switzerland. Electronic address: daniel.fertek@gmail.com.
  • Merberg D; Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA 02141, USA. Electronic address: merbergd@gmail.com.
  • Natarajan M; Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA 02141, USA. Electronic address: madhu@crosswalktx.com.
  • Whiteman DAH; Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, MA 02421, USA. Electronic address: dahw.md@gmail.com.
  • Giugliani R; Department of Genetics/UFRGS, Medical Genetics Service/HCPA, INAGEMP, DASA and Casa dos Raros, Porto Alegre, Brazil. Electronic address: rgiugliani@hcpa.edu.br.
Mol Genet Metab ; 143(1-2): 108576, 2024 Sep 10.
Article en En | MEDLINE | ID: mdl-39303318
ABSTRACT

PURPOSE:

This study investigated the relationship between mucopolysaccharidosis II (MPS II) iduronate-2-sulfatase gene (IDS) variants and phenotypic characteristics, particularly cognitive impairment, using data from the Hunter Outcome Survey (HOS) registry.

METHODS:

HOS data for male patients (n = 650) aged ≥5 years at latest cognitive assessment with available genetic data were analyzed. Predefined genotype categories were used to classify IDS variants and report phenotypic characteristics by genotype.

RESULTS:

At their latest cognitive assessment, 411 (63.2%) of 650 patients had cognitive impairment. Missense variants were the most common MPS II genotype, with about equal frequency for patients with and patients without cognitive impairment. Complete deletions/large rearrangements were associated with cognitive impairment. Cognitive impairment and behavioral issues were most common, and height and weight abnormalities most apparent, in patients with large IDS structural changes. Broadly, missense variants NM-000202.8c.998C>T p.(Ser333Leu), NM-000202.8c.1402C>T p.(Arg468Trp), NM-000202.8c.1403G>A p.(Arg468Gln) and NM-000202.8c.262C>T p.(Arg88Cys), and splice site variant NM-000202.8c.257C>T p.(Pro86Leu), were associated with cognitive impairment, and variants NM-000202.8c.253G>A p.(Ala85Thr), NM-000202.8c.187 A>G p.(Asn63Asp), NM-000202.8c.1037C>T p.(Ala346Val), NM-000202.8c.182C>T p.(Ser61Phe) and NM-000202.8c.1122C>T were not.

CONCLUSION:

This analysis contributes toward the understanding of MPS II genotype-phenotype relationships, confirming and expanding on existing findings in a large, geographically diverse population.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Genet Metab Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA / METABOLISMO Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Genet Metab Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA / METABOLISMO Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos